The submission for the vaccine, codenamed mRNA-1345, will be made on the strength of just-released phase 3 data that showed it had 83.7% efficacy in preventing RSV lower respiratory tract disease (RSV-LRTD) in older adults aged 60 and over.
That timeline represents breakneck speed for the programme, which only started clinical testing a couple of years ago, revealing once again the potential for mRNA to disrupt the usual order of vaccine and therapeutics development.
